Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03865992 · ClinicalTrials.gov registry record · NA

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

A NA study of Breast Cancer and Joint Pain, sponsored by City of Hope Medical Center.

Active
Registry status
NA
Development phase
42
Enrollment target
4
Study locations

NCT03865992: Active NA study of Breast Cancer and Joint Pain, sponsored by City of Hope Medical Center.

NCT03865992 is a NA study of Breast Cancer and Joint Pain that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 42 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03865992, a NA study of Breast Cancer and Joint Pain, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
42 participants
Enrollment target
4
Study locations

Study Summary

This phase I trial studies how well curcumin works in reducing joint pain in patients who are breast cancer survivors and have joint disease caused by treatment with aromatase inhibitors. Curcumin is an ingredient of turmeric, a plant in the ginger family, which is commonly used in curries and South Asian and Middle Eastern cooking, and may decrease joint pain in patients with arthritis from other conditions (such as osteoarthritis and rheumatoid arthritis).

Primary Outcome

The study will assess the feasibility of using the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) to detect changes in aromatase inhibitor (AI)-induced symptoms and well-being in postmenopausal women with breast cancer randomized to 3 months of nanoemulsion curcumin (NEC) versus (vs) placebo capsules.

Conditions Studied

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Placebo
  • DIETARY_SUPPLEMENT Curcumin
  • BEHAVIORAL Questionnaire
  • OTHER Nanoemulsion

Study Locations (4)

California

  • City of Hope Medical Center - Duarte
  • City of Hope Rancho Cucamonga - Rancho Cucamonga
  • City of Hope South Pasadena - South Pasadena

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2019-03-04
Est. Completion 2026-09-08
Phase NA
City of Hope Medical Center

582 total trials

What the registry record for NCT03865992 still lists

NCT03865992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03865992 reports a single indexed study location in California, Ohio.

Frequently Asked Questions

What is clinical trial NCT03865992 about?

NCT03865992 is a clinical study titled "Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease". This phase I trial studies how well curcumin works in reducing joint pain in patients who are breast cancer survivors and have joint disease caused by treatment with aromatase inhibitors. Curcumin is an ingredient of turmeric, a plant in the ginger family, which is commonly used in curries and South...

What is the current status of trial NCT03865992?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2019-03-04. Estimated completion is 2026-09-08.

What conditions does trial NCT03865992 study?

This clinical trial studies the following conditions: Breast Cancer, Joint Pain.

What interventions are being tested in trial NCT03865992?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Curcumin (DIETARY_SUPPLEMENT), Questionnaire (BEHAVIORAL), Nanoemulsion (OTHER).

Who is sponsoring clinical trial NCT03865992?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03865992 being conducted?

This trial has 4 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03865992's enrollment target sits among peer trials

42 864th of 1224 higher than 356 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03865992, the US trial registry maintained by the National Library of Medicine. NCT03865992 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.